New Brunswick Scientific Co., Inc. (NBSC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (605)	1/7/2003 12:30:46 AM
From: scaram(o)uche	of 724

>> progress at a company that shared a general "vision" with DGI << and at yet another (emphasis mine)....... WSJ: Sunesis, Biogen Collaborating To Develop New Drugs Tuesday January 7, 12:15 am ET By David P. Hamilton, Of The Wall Street Journal SOUTH SAN FRANCISCO, Calif. -- Sunesis Pharmaceuticals Inc. has begun a collaboration with Biogen Inc. (NasdaqNM:BGEN - News) , Cambridge, Mass., to develop new drugs for inflammatory and autoimmune diseases, The Wall Street Journal has learned. The deal covers four particular protein targets against which the two companies will develop drugs, as well as options for two additional protein targets. The agreement is potentially worth $60 million per target in loans and payments to Sunesis if development proceeds smoothly, as well as royalties from any successful product. Biogen will receive exclusive worldwide rights to any drug compounds that result. (This and related background will be availabe on The Journal's Web site, WSJ.com.) The work will proceed using Sunesis s fragment-based drug-discovery technology. The so-far unproven technique involves identifying numerous smaller molecules that can bind to portions of the target protein, then tethering these fragment molecules to produce a drug molecule that can be delivered in pill form. -By David P. Hamilton, The Wall Street Journal; (415) 765-6116; david.hamilton@wsj.com Dow Jones Newswires 01-07-03 0015ET

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next